Lidocaine 5% patch

DRUG6 trials

Sponsors

J.A.R. Laboratories, Cook County Health, Nicole K Brogden, Scilex Pharmaceuticals, Inc., Beijing Tiantan Hospital

Conditions

ArthritisBack PainDiabetic Complications NeurologicalDiabetic Nerve ProblemsDiabetic NeuropathyHealthyLidocaineLow Back Pain

Phase 1

Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects

CompletedNCT04144192

Scilex Pharmaceuticals, Inc.Healthy

Start: 2014-04-28End: 2014-07-24Updated: 2024-05-23

Phase 3

Pre-emptive Topical Lidocaine 5% Plaster for Prevention of Post-craniotomy Pain

Beijing Tiantan HospitalLidocaine, Postoperative Pain

Start: 2020-10-15End: 2023-01-31Target: 180Updated: 2020-10-20

Phase 4

Adjunctive 5% Lidocaine Patches for Acute Non-radicular Low Back Pain in Emergency Department Patients

WithdrawnNCT03301766

Cook County HealthLow Back Pain

Start: 2017-03-10End: 2023-05-22Updated: 2023-06-29

Pharmacokinetics of Lidocaine in Healthy Adults

CompletedNCT03310970

Nicole K BrogdenHealthy

Start: 2018-03-14End: 2019-10-09Updated: 2021-11-01

The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Males With Diabetic Neuropathy

CompletedNCT04238208

Corporacion Parc TauliDiabetic Complications Neurological, Diabetic Nerve Problems, Diabetic Neuropathy

Start: 2019-01-10End: 2020-01-02Updated: 2020-01-30

Unknown Phase

Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and Arthritis

J.A.R. LaboratoriesArthritis, Back Pain

Start: 2016-04-30End: 2016-05-31Target: 100Updated: 2016-04-22

Related Papers

Efficacy of Preemptive Topical Lidocaine 5% Plaster in the Prevention of Post-Craniotomy Pain, a Randomized Clinical Trial

Journal of Pain Research2024-12-01

<p>A Randomized, Open-Label, Bioequivalence Study of Lidocaine Topical System 1.8% and Lidocaine Patch 5% in Healthy Subjects</p>

Journal of Pain Research2020-06-0111 citations